BCI
KRYS icon

Brinker Capital Investments’s Krystal Biotech KRYS Stock Holding History

Brinker Capital Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
828
-99
-11% -$26.3K ﹤0.01% 1829
2025
Q4 		$228K Buy
+927
New +$195K ﹤0.01% 1951
2025
Q2 		– Sell
-1,160
Closed -$209K – 2026
2025
Q1 		$209K Buy
+1,160
New +$195K ﹤0.01% 1787
2024
Q4 		– Sell
-1,247
Closed -$227K – 1874
2024
Q3 		$227K Sell
1,247
-77
-6% -$14.8K ﹤0.01% 1657
2024
Q2 		$243K Sell
1,324
-148
-10% -$24.8K ﹤0.01% 1552
2024
Q1 		$262K Buy
+1,472
New +$204K ﹤0.01% 1510

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brinker Capital Investments's KRYS Position: Q1 2026 in Review

Brinker Capital Investments reduced its Krystal Biotech (KRYS) stake by 11% in Q1 2026, selling an estimated $26.3K and leaving 828 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Brinker Capital Investments first reported a position in KRYS in Q1 2024 and has held it in 6 quarters since. The position peaked at $262K in Q1 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Brinker Capital Investments held 828 shares of Krystal Biotech worth $214K as of Q1 2026.
  • Brinker Capital Investments sold 99 Krystal Biotech shares in Q1 2026, an estimated $26.3K.
  • Krystal Biotech made up ﹤0.01% of Brinker Capital Investments's portfolio in Q1 2026, its #1829 holding.
  • Brinker Capital Investments first reported a position in Krystal Biotech in Q1 2024 and has held it in 6 quarters since.
  • Brinker Capital Investments's Krystal Biotech position peaked at $262K in Q1 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.